Risk assessment pharmacokinetic modeling

Risk Assessment. This model successfully described the disposition of chloroform in rats, mice and humans following various exposure scenarios and developed dose surrogates more closely related to toxicity response. With regard to target tissue dosimetry, the Corley model predicts the relative order of susceptibility to chloroform toxicity consequent to binding to macromolecules (MMB) to be mouse > rat > human. Linking the pharmacokinetic parameters of this model to the pharmacodynamic cancer model of Reitz et al. (1990) provides a biologically based risk assessment model for chloroform. 

Sixth, and finally, the adequacy of model structure as well as parameter values should be evaluated based on comparison of mode predictions with experimental data that had not been used for calibration purpose. This process essentially evaluates whether the PBPK model is capable of providing reliable predictions of the various dose metrics of potential use in a cancer risk assessement. The model should not only reprodnce consistently the shape of the pharmacokinetic time-course curve (i.e., including bnmps and valleys) and not jnst provide satisfactory fit only to a portion of the cnrve. Evaluation or validation of PBPK models should be regarded... 

Risk assessment. The model was designed to simulate the pharmacokinetics of selenium orally administered as selenite to humans as a preparation for a larger anticancer supplementation study jointly undertaken by the National Cancer Institute (NCI) and the U.S. Department of Agriculture (USDA) (Patterson and Zech 1992 Patterson et al. 1991,1993). 

PBPK models improve the pharmacokinetic extrapolations used in risk assessments that identify the maximal (i.e., the safe) levels for human exposure to chemical substances (Andersen and Krishnan 1994). PBPK models provide a scientifically sound means to predict the target tissue dose of chemicals in humans who are exposed to environmental levels (for example, levels that might occur at hazardous waste sites) based on the results of studies where doses were higher or were administered in different species. Figure 3-4 shows a conceptualized representation of a PBPK model. 

Notice Approaches for the Application of Physiologically-Based Pharmacokinetic (PBPK) Models and Supporting Data in Risk Assessment E-Docket ID No. ORD-2005-0022. Fed Reg July 28, 2005 70 (144) 43692-43693. 

Clewell HJ 3rd, Gentry PR, Covington TR, Gearhart JM. Development of a physiologically based pharmacokinetic model of trichloroethylene and its metabolites for use in risk assessment. Environ Health Perspect 2000 May 108 Suppl 2 283-305. 

Cronin WJ, Oswald EJ, Shelley ML, et al. 1995. A trichloroethylene risk assessment using a Monte Carlo analysis of parameter uncertainty in conjunction with physiologically-based pharmacokinetic modeling. Risk Anal 15 555-565. 

Absorbed lead is distributed in various tissue compartments. Several models of lead pharmacokinetics have been proposed to characterize such parameters as intercompartmental lead exchange rates, retention of lead in various pools, and relative rates of distribution among the tissue groups. See Section 2.3.5 for a discussion of the classical compartmental models and physiologically based pharmacokinetic models (PBPK) developed for lead risk assessments. 

PBPK and classical pharmacokinetic models both have valid applications in lead risk assessment. Both approaches can incorporate capacity-limited or nonlinear kinetic behavior in parameter estimates. An advantage of classical pharmacokinetic models is that, because the kinetic characteristics of the compartments of which they are composed are not constrained, a best possible fit to empirical data can be arrived at by varying the values of the parameters (O Flaherty 1987). However, such models are not readily extrapolated to other species because the parameters do not have precise physiological correlates. Compartmental models developed to date also do not simulate changes in bone metabolism, tissue volumes, blood flow rates, and enzyme activities associated with pregnancy, adverse nutritional states, aging, or osteoporotic diseases. Therefore, extrapolation of classical compartmental model simulations... 

O Flaherty EJ. 1987. Modeling An introduction. In Pharmacokinetics in risk assessment Drinking water and health, vol 8. National Academy of Sciences, Washington, D.C. National Academy Press, 27-3. 

Other major early contributions of biochemical engineering have been in the development of the artificial kidney and physiologically based pharmacokinetic models. The artificial kidney has been literally a lifesaver. Pharmacokinetic models divide the body of an animal or human into various compartments that act as bioreactors. These mathematical models have been used very successfully in developing therapeutic strategies for the optimal delivery of chemotherapeutic drugs and in assessing risk from exposure to toxins. 

Andersen, M.E., J.J. Mills, M.L. Gargas, L. Kedderis, L.S. Bimbaum, D. Neubert, and W.F. Greenlee. 1993. Modeling receptor-mediated processes with dioxin implications for pharmacokinetics and risk assessment. Risk Analysis 13 25-36. 

Andersen ME (1995) Development of physiologically based pharmacokinetic and physiologically based pharmacodynamic models for applications in toxicology and risk assessment. Toxicol Lett 79 35-44... 

Connally, R. and Anderson, M. (1991). Biologically based pharmacokinetic models Tools for toxicological research risk assessment. Annu. Rev. Pharmacol. Toxicol. 31 503-523. 

Many laboratory animal models have been used to describe the toxicity and pharmacology of chloroform. By far, the most commonly used laboratory animal species are the rat and mouse models. Generally, the pharmacokinetic and toxicokinetic data gathered from rats and mice compare favorably with the limited information available from human studies. PBPK models have been developed using pharmacokinetic and toxicokinetic data for use in risk assessment work for the human. The models are discussed in depth in Section 2.3.5. As mentioned previously, male mice have a sex-related tendency to develop severe renal disease when exposed to chloroform, particularly by the inhalation and oral exposure routes. This effect appears to be species-related as well, since experiments in rabbits and guinea pigs found no sex-related differences in renal toxicity. 

Clewell HJ III, Andersen ME. 1985. Risk assessment extrapolations using physiologically-based pharmacokinetic modeling. Toxicol Ind Health 1 111-131. 

PBPK models improve the pharmacokinetic extrapolations used in risk assessments that identify the maximal (i.e., the safe) levels for human exposme to ehemieal substanees (Andersen and Krishnan 1994). 

---